Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Fulcrum Therapeutics's FCF Margin % or its related term are showing as below:
During the past 9 years, the highest FCF Margin % of Fulcrum Therapeutics was -3.12%. The lowest was -3261.07%. And the median was -623.34%.
FULC's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -77.885 * Ranked among companies with meaningful FCF Margin % only.
The historical data trend for Fulcrum Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fulcrum Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulcrum Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Fulcrum Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulcrum Therapeutics (FULC) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fulcrum Therapeutics and its competitors. According to the industry distribution chart, Fulcrum Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry.
Is Fulcrum Therapeutics' FCF Margin % too high?
Fulcrum Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Fulcrum Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fulcrum Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulcrum Therapeutics' FCF Margin % compare to AGEN and IRD?
According to the Biotechnology industry distribution chart, Fulcrum Therapeutics ranks #999999 out of 954 companies for FCF Margin %. This places Fulcrum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fulcrum Therapeutics and its competitors. Fulcrum Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulcrum Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fulcrum Therapeutics (FULC) is currently considered Possible Value Trap. The stock's GF Value™ is $32.03, compared to a current price of $3.73 — trading 88.4% below its estimated fair value. The current FCF Margin % is 0.00%. Fulcrum Therapeutics' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Fulcrum Therapeutics (FULC), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulcrum Therapeutics (FULC) Overvalued in 2026?
Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued.
The current stock price of $3.73 is trading 88.4% below its estimated GF Value™ of $32.03.
GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.
Key valuation signals for FULC:
FCF Margin %: 0.00%
GF Value™: $32.03 vs. price of $3.73 (88.4% below fair value)
No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score
Get the complete analysis for FULC
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FULC has been successfully added to your 
